Last reviewed · How we verify

UFT, Calcium Folinate

Iwate Medical University · Phase 3 active Small molecule ✓ Verified May 2026

UFT, Calcium Folinate is a Antimetabolite Small molecule drug developed by Iwate Medical University. It is currently in Phase 3 development for Colorectal cancer, Gastric cancer.

UFT is a prodrug that is converted into 5-fluorouracil, which inhibits thymidylate synthase, leading to DNA damage and cell death.

Calcium Folinate is a small molecule with an unknown mechanism of action. It is used in combination with other chemotherapy agents, such as 5-fluorouracil and leucovorin calcium, to treat conditions including colorectal cancer, breast cancer, and unspecified adult solid tumors.

Likelihood of approval
61.3% vs 58.3% industry baseline
If approved by FDA: likely 2028–2030
Steps remaining: NDA/BLA submission
Confidence: High
Why this estimate
  • Baseline phase 3 → approval rate +58.3pp
    Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
  • Oncology Phase 3 boost +3.0pp
    Oncology Phase 3 trials have higher approval rates (~61%) than the cross-industry average due to clearer endpoints and FDA oncology pathway.
Predicted approval windows by jurisdiction (conditional on FDA approval)
Regulator Country Likely year Lag vs FDA
FDA US 2028–2030
EMA EU 2029–2031 +0.7 yr
MHRA GB 2029–2031 +0.7 yr
Health Canada CA 2029–2032 +0.9 yr
TGA AU 2029–2032 +1.2 yr
PMDA JP 2029–2032 +1.5 yr
NMPA CN 2030–2033 +2.3 yr
MFDS KR 2029–2032 +1.4 yr
CDSCO IN 2029–2033 +1.8 yr
ANVISA BR 2030–2033 +2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic nameUFT, Calcium Folinate
SponsorIwate Medical University
Drug classAntimetabolite
TargetThymidylate synthase
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

Calcium folinate is used to counteract the toxic effects of 5-fluorouracil on the bone marrow and mucosa. It works by replenishing folate stores and helping to maintain normal DNA synthesis.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about UFT, Calcium Folinate

What is UFT, Calcium Folinate?

UFT, Calcium Folinate is a Antimetabolite drug developed by Iwate Medical University, indicated for Colorectal cancer, Gastric cancer.

How does UFT, Calcium Folinate work?

UFT is a prodrug that is converted into 5-fluorouracil, which inhibits thymidylate synthase, leading to DNA damage and cell death.

What is UFT, Calcium Folinate used for?

UFT, Calcium Folinate is indicated for Colorectal cancer, Gastric cancer.

Who makes UFT, Calcium Folinate?

UFT, Calcium Folinate is developed by Iwate Medical University (see full Iwate Medical University pipeline at /company/iwate-medical-university).

What drug class is UFT, Calcium Folinate in?

UFT, Calcium Folinate belongs to the Antimetabolite class. See all Antimetabolite drugs at /class/antimetabolite.

What development phase is UFT, Calcium Folinate in?

UFT, Calcium Folinate is in Phase 3.

What are the side effects of UFT, Calcium Folinate?

Common side effects of UFT, Calcium Folinate include Diarrhea, Nausea, Vomiting, Mucositis, Leukopenia.

What does UFT, Calcium Folinate target?

UFT, Calcium Folinate targets Thymidylate synthase and is a Antimetabolite.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing